Citation Impact
Citing Papers
Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2
2011 Standout
IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat
2009
Dendritic cell–expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice
2007 StandoutNobel
The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas
2001 Standout
Enhanced expression of PDX-1 and Ngn3 by exendin-4 during β cell regeneration in STZ-treated mice
2005
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
2002
Mechanism of Inhibition of Protein-tyrosine Phosphatases by Vanadate and Pervanadate
1997 Standout
The enigma of ceramide synthase regulation in mammalian cells
2016
Peroxovanadium compounds: Biolgoical actions and mechanism of insulin-mimesis
1995
Minireview: Glucagon-Like Peptides Regulate Cell Proliferation and Apoptosis in the Pancreas, Gut, and Central Nervous System
2004
Microbial tryptophan catabolites in health and disease
2018 Standout
Newly Synthesized Phosphatidylinositol Phosphates Are Required for Synaptic Norepinephrine but Not Glutamate or γ-Aminobutyric Acid (GABA) Release
1998 StandoutNobel
Sphingolipids and their metabolism in physiology and disease
2017 Standout
Activated PKR inhibits pancreatic β-cell proliferation through sumoylation-dependent stabilization of P53
2015
Abnormal Cell Calcium Homeostasis in Type 2 Diabetes Mellitus: A New Look on Old Disease
1999
Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling
1995
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
The biology of incretin hormones
2006 Standout
The changing landscape of atherosclerosis
2021 StandoutNature
Characterization of low dose streptozotocin-induced progressive diabetes in mice
2001
Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors.
1992
Type 2 diabetes as an inflammatory disease
2011 Standout
The Glucagon‐Like Peptides
2006
Obesity
2005 Standout
Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway
1999 Standout
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
2020 Standout
Activation of microglial N‐methyl‐D‐aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain
2012
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
2006
Biology of Incretins: GLP-1 and GIP
2007 Standout
Stimulated Release of Size‐Selected Cargos in Succession from Mesoporous Silica Nanoparticles
2012 StandoutNobel
Prolonged increase of plasma non-esterified fatty acids fully abolishes the stimulatory effect of 24 hours of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men
2004
Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling
1995 Standout
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
2006 Standout
Type 2 diabetes
2017 Standout
Glucagon-like peptide 1(GLP-1) in biology and pathology
2005
Vanadium treatment of diabetic Sprague-Dawley rats results in tissue vanadium accumulation and pro-oxidant effects
1993
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
2017 Standout
Mechanisms linking obesity to insulin resistance and type 2 diabetes
2006 StandoutNature
Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression in db/db Mice
2003
How were new medicines discovered?
2011 Standout
Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan
2004
The relationship of diabetes, loss of glucose-induced insulin secretion, and GLUT2
1993
Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets
2003
Oxidative mechanisms in the toxicity of metal ions
1995 Standout
Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors
2004
Toxicology of vanadium compounds in diabetic rats: The action of chelating agents on vanadium accumulation
1995
N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress
2003
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
2006
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice
2002
The Physiology of Glucagon-like Peptide 1
2007 Standout
Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology
2022 Standout
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
2009
The hormone resistin links obesity to diabetes
2001 StandoutNature
Developmental programming of type 2 diabetes
2015
Ferroptosis: mechanisms, biology and role in disease
2021 Standout
The interplay between cytokines and the Kynurenine pathway in inflammation and atherosclerosis
2017
Programming of intermediary metabolism
2001
Inflammation, metaflammation and immunometabolic disorders
2017 StandoutNature
Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.
1987
Insulin Signaling and Glucose Transport in Insulin Resistant Skeletal Muscle
1998
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
2003
In vivo effects of peroxovanadium compounds in BB rats
1995
Prediabetes: a high-risk state for diabetes development
2012 Standout
The endocrine pancreas in non‐diabetic rats after short‐term and long‐term treatment with the long‐acting GLP‐1 derivative NN2211
2003
Metabolic effects of vanadyl sulfate in humans with non—insulin-dependent diabetes mellitus: In vivo and in vitro studies
2000
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines
1999 Standout
Antioxidant α‐tocopherol ameliorates glycemic control of GK rats, a model of type 2 diabetes
2000
Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: A Review of Emerging Therapies for Type 2 Diabetes
2006
In vivo effects of peroxovanadium compounds in BB rats
1995
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
2009 Standout
Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes
2006
Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction
2006 Standout
Adaptation of β-cell mass to substrate oversupply: enhanced function with normal gene expression
2001
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
The Role of Vitamin D and Calcium in Type 2 Diabetes. A Systematic Review and Meta-Analysis
2007 Standout
Type 2 diabetes: principles of pathogenesis and therapy
2005 Standout
Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes
2003
Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans
1992
GENETICS OF NON-INSULIN-DEPENDENT (TYPE-II) DIABETES MELLITUS
1996
Vanadium and diabetes.
1998
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Diabetes and Cancer
2010 Standout
1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties
2003
Combination Therapy With Glucagon-Like Peptide-1 and Gastrin Restores Normoglycemia in Diabetic NOD Mice
2008
Cure of Overt Diabetes in NOD Mice by Transient Treatment With Anti-Lymphocyte Serum and Exendin-4
2004
Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics.
1994
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
2002 Standout
The Chemistry and Biochemistry of Vanadium and the Biological Activities Exerted by Vanadium Compounds
2004 Standout
Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent?
2000
Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes
2003
Therapeutic Strategies Based on Glucagon-Like Peptide 1
2004
Mechanisms of Diabetic Complications
2013 Standout
Vanadium and diabetes
1998
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
2003 Standout
Reactive Oxygen Species in Metabolic and Inflammatory Signaling
2018 Standout
Differential Effects of Hyperlipidemia on Insulin Secretion in Islets of Langerhans From Hyperglycemic Versus Normoglycemic Rats
2002
daf-2 , an Insulin Receptor-Like Gene That Regulates Longevity and Diapause in Caenorhabditis elegans
1997 StandoutScienceNobel
Glucose-dependent Insulinotropic Polypeptide Activates the Raf-Mek1/2-ERK1/2 Module via a Cyclic AMP/cAMP-dependent Protein Kinase/Rap1-mediated Pathway
2002
Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors
2004
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
2005
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice
2002
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1)
2006
Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat
2003
Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats
2003
Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
2003
Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies.
1995
Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects
1996
Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions.
1986
Deletion of Pten in Pancreatic β-Cells Protects Against Deficient β-Cell Mass and Function in Mouse Models of Type 2 Diabetes
2010 StandoutNobel
Physiology of Microglia
2011 Standout
Improved Glucose Tolerance Restores Insulin-Stimulated Akt Kinase Activity and Glucose Transport in Skeletal Muscle From Diabetic Goto-Kakizaki Rats
1997
Works of Danielle Bailbé being referenced
The toxicity of H2O2 on the ionic homeostasis of airway epithelial cells in vitro
2003
Expression of the kynurenine pathway enzymes in the pancreatic islet cells. Activation by cytokines and glucolipotoxicity
2015
Underfeeding of rat mothers during the first two trimesters of gestation does not alter insulin action and insulin secretion in the progeny
1995
Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: Evidence for reversal following phlorizin treatment
1990
Differential Effects of Prolonged Hyperglycemia onin Vivoandin VitroInsulin Secretion in Rats
1991
In vivo insulin resistance in streptozotocin-diabetic rats ? evidence for reversal following oral vanadate treatment
1989
Maternal diabetes, programming of beta-cell disorders and intergenerational risk of type 2 diabetes
2014
Impairment of the mitochondrial oxidative response to D-glucose in pancreatic islets from adult rats injected with streptozotocin during the neonatal period
1990
Effect of gliclazide treatment on insulin secretion and β-cell mass in non-insulin dependent diabetic Goto–Kakisaki rats
1998
Abnormal B-Cell Function in Rats with Non-Insulin-Dependent Diabetes Induced by Neonatal Streptozotocin
1991
Importance of Mitochondrial Dynamin-Related Protein 1 in Hypothalamic Glucose Sensitivity in Rats
2012
Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the β-Cell Mass During the Prediabetic Period With Glucagon-Like Peptide-1 or Exendin-4
2002
Glucose insensitivity and amino-acid hypersensitivity of insulin release in rats with non-insulin-dependent diabetes. A study with the perfused pancreas
1983
Ceramide synthase 4 and de novo production of ceramides with specific N-acyl chain lengths are involved in glucolipotoxicity-induced apoptosis of INS-1 β-cells
2011
Impairment of glycerol phosphate shuttle in islets from rats with diabetes induced by neonatal streptozocin
1991
β-Cell Insensitivity to Glucose in the GK Rat, a Spontaneous Nonobese Model for Type II Diabetes
1991
Insulin treatment improves glucose-induced insulin release in rats with NIDDM induced by streptozocin
1987
Glucose Insensitivity and Amino-acid Hypersensitivity of Insulin Release in Rats with Non-insulin-dependent Diabetes: A Study with the Perfused Pancreas
1983
Impaired insulin secretion and excessive hepatic glucose production are both early events in the diabetic GK rat
1996
Insulin Treatment Improves Glucose-Induced Insulin Release in Rats With NIDDM Induced by Streptozocin
1987
Beta-cell insensitivity to glucose in the GK rat, a spontaneous nonobese model for type II diabetes
1991
Glucagon-Like Peptide-1 and Exendin-4 Stimulate β-Cell Neogenesis in Streptozotocin-Treated Newborn Rats Resulting in Persistently Improved Glucose Homeostasis at Adult Age
2001